Man Group PLC Cure Vac N.V. Transaction History

Man Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.75 - $8.5 $1.36 Million - $2.01 Million	-236,047 Reduced 83.71%	45,949 $277,000
Q3 2022 Nov 14, 2022	BUY	$7.48 - $15.24 $1.79 Million - $3.65 Million	239,624 Added 565.52%	281,996 $2.22 Million
Q2 2022 Aug 15, 2022	BUY	$13.18 - $19.41 $558,462 - $822,440	42,372 New	42,372 $577,000
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $392,736 - $561,618	-11,647 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $573,731 - $867,701	11,647 New	11,647 $636,000
Q1 2021 May 17, 2021	SELL	$79.79 - $126.29 $394,401 - $624,251	-4,943 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $231,134 - $673,582	4,943 New	4,943 $401,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.